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Summary 
While interactions between CD28 and members of the B7 family costimulate and enhance T 
cell responses,  recent evidence indicates that the CD28 homologue CTLA-4 plays a downreg- 
ulatory role. The mechanism by which this occurs is not clear, but it has been suggested that 
CTLA-4 terminates ongoing responses  of activated T  cells, perhaps by induction of apoptosis. 
Here we demonstrate that CTLA-4 engagement by antibody cross-linking or binding to B7 
inhibits proliferation and accumulation of the primary T  cell growth factor, IL-2, by cells stim- 
ulated with anti-CD3 and anti-CD28.  This inhibition is not a result of enhanced cell death. 
Rather it appears  to result from restriction of transition from the G1  to the S phase of the cell 
cycle. Our observation that upregulation of both the IL-2K alpha chain and the CD69 activa- 
tion antigen are inhibited by CTLA-4 engagement supplies further evidence that CTLA-4 re- 
stricts  the progression  of T  cells  to  an  activated state.  Together this data demonstrates that 
CTLA-4 can regulate T cell activation in the absence of induction ofapoptotic cell death, 
I 
t  has by now become  generally accepted that the  out- 
come of T cell antigen receptor occupancy is strongly in- 
fluenced by costimulatory signals provided by interactions 
between CD28 on the T  cell surface and its ligands  B7-1 
(CD80)  and B7-2  (CD86)  on  the antigen-presenting cell 
(1-3).  These r  signals enhance production of 
several  lymphokines, especially  IL-2.  and greatly increase 
proliferation, An additional effect of CD28 cosfimulation is 
the induction of expression ofbcl-xL, which has been asso- 
ciated with enhanced T  cell starvival (4). Recent findings 
suggest  that  the  CD28  homologue  CTLA-4  which,  hke 
CD28,  binds members of the B7 family, also plays a very 
important role in the outcome ofT cell activation, 
A  role  for CTLA-4 in  T  cell activation was  originally 
suggested by the fact that antibodies to CTLA-4, while not 
themselves costimulatory, augmented proliferation oft  cells 
costimulated by anti-CD28 (5). It was subsequently shown 
that  both  intact anti-CTLA-4  and  its  Fab  fragments en- 
hanced T cell proliferative responses  in vitro, and that both 
soluble anti-CTLA-4 and anti-B7 antibodies enhanced pro- 
liferation ofT cells activated by anti-CD3 and co~imulated 
with anti-CD28 (6,  7),  On the other hand, anti-CTLA-4 
antibodies inhibited T cell proli~ration when Fc receptor- 
mediated cro~s-linking was available  or when cross-linked 
or presented in immobilized form together with arlti-CD3 
and anti-CD28 (fi, 7),  Together, these reslal/s suggested an 
inhibitory rote for CTLA-4,  This notion was further sup- 
ported by demonstrations that in vivo blockade of CTLA- 
~I/B7 interaction by either intact CTLA-4 antibody or i.ts 
Fab fragment increased the expansion ofT cells reactive with 
a specific peptide antigen or the superantigen Staphylococ- 
cus enterotoxin B (SEB) (8, 9). Finally, recent reports have 
documented a rampant T cell lymphocytic prohferative dis- 
order with early leflaality in  CTLA-4-deficient mice  (10, 
11), Together, these findings demonstrate that CD28  and 
CTLA-4 have opposing effects on T cell activation, and that 
CTLA-4 has a very important role in downregulation of T 
cell responses. 
The mechanism of CTLA-4 inhibition ofT cell responses 
is  not  clear.  Since  CTLA-4  expression  reaches  maximal 
levels by T cells 2-3 d after activation, it has been suggested 
that its role is to terminate T cell responses at that point and 
facilitate  the  generation  of memory T  cells  ready to  re- 
spond to antigen after decay of CTLA-4 expression (1,  3, 
12,  13), Altern,atively  it has been suggested that CTLA-4 
signaling might terminate T  cell responses  by inducing cell 
death by an apoptotic mechanism (14). In support of this 
possibjli.ty, it has been reported that an anti-CTLA=4 anti- 
body, although not the known B7 ligands,  can induce cell 
death in activated T celt elor~es (15). 
Here we report a kineti.c analysis of  the effects of CTLA-4 
ligation on prohferation, IL-2 production, cell death, .cell cy- 
cle progression, and die appearance oft cell activation mark- 
ers, By blockade of CTLA-4/B7 interactions and by anti- 
body-mediated cross,,linking we demonstrate that CTLA-4 
ligation inhibits T  cell proliferation and IL-2 accumulation. 
These responses  are  not precipitously terminated once es- 
tablished, but are delayed and diminished. There is no evi- 
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at any time during the response. Inhibition of the prolifera- 
tive response appears to be a consequence of arrest in the 
G0/G1 stage of the cell cycle perhaps as a consequence of 
diminished IL-2 production and inhibition  of expression of 
the IL-2 receptor alpha chain. Finally, we show that CTLA-4 
ligation also inhibits expression of CD69,  an early marker 
of T  cell activation. These data are not consistent with in- 
hibition by induction of cell death.  Rather,  they  suggest 
that CTLA-4 can restrict the transition ofT cells to an acti- 
vated state. 
Materials  and Methods 
Antibodies and Reagents.  Antibodies used for activation were: 
anti-CD3 (hybridoma  500A2 [16]), anti-CD28 (hybridoma 37.N. 
51.1 [17]), anti-CTLA-4 (hybridoma 9H10.11G3 [7]), and anti- 
V~/3 (hybridoma 536 [18]). CTLA-4Ig was a kind gift ofDrs. K. 
Karljialeinen and P.  Lane  (19). APC  and  CD8  depletion was 
achieved using anti-Class II MHC (hybridomas 28-16-8s [20] and 
BP107  [21]), and anti-CD8 antibodies (hybridoma 3.155  [22]). 
Sulfate polystyrene latex microspheres of 5 -  0.1 ~M mean diam- 
eter were obtained from Inteffacial Dynamics Corp. (Portland, OIL). 
Preparation ofCD4+  TLymphocytes.  Lymph node cells were 
isolated from 6-8-wk-old BALB/c mice obtained from National 
Cancer Institute (Bethesda, MD). Isolated lymphocytes were ob- 
tained by the mincing of tissue and filtration of the resulting sus- 
pension through nytex. Enriched CD4+ T cell preparations were 
obtained by treatment with complement, anti-Class II antibodies, 
and anti-CD8 antibodies as described  (23). Typical preparations 
were 95% CD4+ with less than 0.75% B220 positive cells. 
Activation of CD4+  T Cells Using lmmobilized Anti-CD3.  Round- 
bottom 96-well plates were coated with anti-CD3 at 0.1 ~g/m/ 
in  50-~1  vol  for  2  h  at  37~  then  washed  extensively and 
blocked for 30 min at 37~  with complete ILPMI-1640 (contain- 
ing 10% FCS, 50 ~M J3-mercaptoethanol,  2 mM glutamine, and 
50 ~g/ml gentamycin). T cells were added at 1 ￿  10  s per well in 
200 ~1 of complete RPMl-1640 and all cultures were incubated 
at 37~  in 5% CO2. Where indicated anti-CD28 was added at 10 
~g/m/, CTLA-4Ig was added  at 5 ~g/m/, and control or anti- 
CTLA-4 FAb fragments  were added at  50  IJog/m/. 12 h  before 
harvest, wells were pulsed with 20 ~1 of complete RPMI contain- 
ing 1 ~Ci of [3H]thymidine.  Plates were harvested  to glass filter 
mats  and  3H  incorporation was  measured  using  a  gas-phase 
counter (Packard, Meriden, CT). 
Activation of T cells Using Latex Microspheres.  Latex  microspheres 
(beads) were coated  as described  (7). Briefly,  1 X  107 beads/m/ 
were suspended in PBS with the indicated antibodies and incu- 
bated  for  1.5  h  at  37~  followed by washing with  PBS  and 
blocking with 10% FCS. Anti-CD3 was added at 0.5 ~g/m/, anti- 
CD28 was added at 1 ~g/m/, anti-CTLA-4 was added at 4 ~g/m/, 
and binding  solutions were normalized with control antibody 536 
to maintain a constant total  antibody concentration of 6 I.Lg/ml 
during binding. T cells (1  ￿  10s/200 IXl) were cultured with 1 ￿ 
10  s beads in a total volume of 200 p  J/well. ILound-bottom 96- 
well plates were used for all assays. Cultures were incubated at 
37~  in 5% CO2 and pulsed with 1 ~Ci of [3H]thymidine for the 
final  12 h  before  harvesting.  The inhibitory action of CTLA-4 
appears specific to anti-CTLA-4 antibodies as other T  cell bind- 
ing antibodies including anti-L selectin  (Mel-14),  anti-Thyl.2 
and irrelevant antibodies show either no effect or augmentatory 
effects when coimmobilized  with anti-CD3 and anti-CD28. 
Analysis of Cell Viability.  T cells were cultured identically as for 
proliferation assays. At the indicated times,  cell viability was as- 
sessed by the addition of one-tenth volume of 0.4% trypan blue 
(Sigma,  St.  Louis,  MO)  and cell  numbers determined using a 
hemocytometer.  10  -4 I111 of each  culture was counted from du- 
plicate wells and the value for this volume was multiplied by 2 to 
obtain a value for the percent of input (50 ￿  10  4 cells/m1 was in- 
put). Standard deviations were always less than 10%. 
Cell Cycle Analysis.  Propidium iodide analysis of cell cycle sta- 
tus was performed as previously described  (24). Briefly, cells were 
activated as described using microspheres  in 96-well plates as de- 
scribed for proliferation assays. At the indicated times, three iden- 
tical wells (3  ￿  105 input at the beginning of culture per sample) 
were harvested,  washed  in PBS,  and fixed  with  1.0 ml of 80% 
ethanol. Cells were incubated on ice for 30 min, pelleted by cen- 
trifugation and resuspended in 0.4 ml of an aqueous solution con- 
taining  0.1%  Triton  X-100,  0.1  mM  EDTA,  0.05  mg/ml 
RNaseA (50 U/mg), and 50  p,g/rnl propidium iodide. Samples 
were stored on ice in the dark until analysis and each sample was 
analyzed at a constant flow rate for 2 min. Data was analyzed us- 
ing a Coulter EPICS system (Coulter Corp., Hialeah,  FL). 
IL-2 Determination.  An ELISA was used to detect IL-2 in cell 
supernatants.  Briefly, capture  antibodies were coated  at  I  p,g/m/ 
onto Coming (Coming, NY) ELISA plates in Borate Buffer (0.2 M 
Na  Borate,  pH  8.0)  for  2  h  at  37~  These  plates  were  then 
washed extensively, blocked with 0.4% Gelatin/PBS for 30 min- 
utes, and then T cell culture supematants (50 p,1) were added and 
incubated for 2 h at 37~  Plates were again washed and biotiny- 
lated  detection antibodies were added  in PBS/0.5% Tween and 
incubated for l  h at 37~  Plates were again washed and 50 p,l of 
a solution of 1 Ixg/nfi  Streptavidin-HRPO in PBS/Tween was 
added and incubated for 30 rain at 37~  50 I,1 of developing re- 
agent (0.55 mg/m/ABTS (2,2'-Azino-bis(3-ethylbenzthiazoline- 
6-sulfonic acid) in citrate buffer ([0.1 M citric acid, pH 4.35]) was 
added,  incubated at 25~  for 15 min, and absorbence at 405 nm 
was  determined. Recombinant IL-2 was  obtained from Boeh- 
ringer Mannheim Corp. (Indianapolis, IN) and was diluted in se- 
ries to develop a standard  curve.  Triplicate absorbence values of 
test  samples  were  thereby  converted to  lymphokine quantities 
measured in nanograms per milliliter.  Antibodies (capture: JES6- 
1A12 and detection: biotinytated  JES6-5H4) were obtained from 
PharMingen (San Diego, CA). 
Analysis of CD25 and CD69 Expression.  2 ￿  l0  s cells were sus- 
pended  in  50  p,1  ice-cold  PBS/1%  calf serum/0.05%  sodium 
azide. Anti-CD25.FITC, anti-CD69, or control Rat IgG FITC 
antibodies were added,  incubated on ice for 30 min followed by 
two  4-m/washes in PBS/calf serum/NaAzide. 5,000  live gated 
events were acquired on a FACScan  |  and the LYSIS II program 
was used to analyze relevant populations. 
Results 
CTLA-4 Engagement Inhibits Proliferation and IL-2 Produc- 
tion.  We have previously shown that soluble antibodies to 
CTLA-4 or B7 increased thymidine incorporation and IL-2 
production by T  cells activated by immobilized anti-CD3 
and anti-CD28 in standard 3-d assays (7).  These results in- 
dicated that blockade of CTLA-4/B7 interactions between 
the  T  cells themselves augmented responses by removing 
inhibitory signals. Since the cultures were assayed at a sin- 
gle time point it was not possible to determine when in the 
course of the cultures the effect occurred. A kinetic analysis 
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of purified CD4+  T  cells is presented in Fig.  1 A. As ex- 
pected  from  our  previous  results  (7),  inclusion of either 
CTLA-4Ig or  Fab  fragments of anti-CTLA-4 to  cultures 
stimulated with anti-CD3 and anti-CD28 resulted in an in- 
crease  in  proliferation.  The  effect  was  slight  at  26  h,  at 
which time there was only marginal proliferation in any of 
the cultures. At later time points CTLA-4/B7  blockade re- 
sulted  in  a  1.5-2-fold increase  in proliferation.  The  en- 
hancing effect of this blockade was even more apparent at 
the level of IL-2 production. As shown in Fig.  1 B,  IL-2 
was detectable, although at low levels, in anti-CD3/CD28 
stimulated cultures by 26  h.  The  addition of either anti- 
CTLA-4 Fab or CTLA-4Ig resulted in an increase of about 
sixfold in the  amount of IL-2 accumulated by 26  h,  and 
nearly ten fold by 40 h. 
We also examined the kinetics of the inhibition of pro- 
liferation and  IL-2  production by  cross-linking CTLA-4 
together with CD3  and CD28 using antibody coated mi- 
crospheres. We have previously reported that CTLA-4 cross- 
linking results in a decrease in thymidine incorporation by 
T  ceils stimulated by anti-CD3 and anti-CD28 in 3-d as- 
says  (7).  This effect is specific to CTLA-4, since irrelevant 
hamster  antibodies  (anti-V3'3)  or  other  antibodies which 
bind to T  cells (anti-L-selectin, anti-Thyl.2) either have no 
effect  or  slightly augment proliferation when  coimmobi- 
lized with anti-CD3 and anti-CD28 (data not shown). The 
kinetics ofthymidine incorporation are shown in Fig.  1 C. 
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Figure 1.  CTLA-4 engagement  inhibits T cell proliferation  and IL-2 production by anti-CD3 and anti-CD28. (./t and B) Blockade of CTLA-4 en- 
gagement inhibits Proliferation  and IL-2 Accumulation.  CD4+ T cells were cultured  in round bottom wells  which had been precoated with 50 p.1 of 0.1 
lig/ml solution of anti-CD3. Anti-CD28 was added in soluble  form at 10 Ixg/ml, CTLA-4Ig was added at 5 Izg/ml, and control or anti-CTLA-4 FAb 
fragments were added at 50 Izg/ml. (/t) 12 h before the indicated  harvest times, cultures  were pulsed with 1 IzCi of [3H]thymidine.  Triplicate  wells were 
harvested and counted. (B) Supematants  were sampled at the indicated times and analyzed  for 1L-2 using a capture ELISA. (C and/9). Proliferation  and 
[L-2 is inhibited by cross-hnking  CTLA-4. CD4+ LNT cells were activated with microspheres coated with the indicated antibodies. (C) Proliferation 
was analyzed  over the 12 h before the indicated  times as described for A. (D) At the indicated  times supernatant  was harvested from cultures  and analyzed 
for IL-2 content using an ELISA assay. 
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stimulated  by anti-CD3  and anti-CD28.  There was essen- 
tially  no  incorporation  detectable  at  26  h  when  CTLA-4 
was also engaged,  and proliferation  was three-  to fourfold 
lower  in  these  cultures  throughout  the  assay  period.  As 
shown in Fig. 1 D, an even more pronounced inhibition of 
IL-2 production was observed.  IL-2 was readily detectable 
in  anti-CD3/CI)28  stimulated  cultures  by  16  h,  and  in- 
creased up to 40 h. When CTLA-4 was also engaged, IL-2 
was  only barely detectable  even  after 30 h,  and  reafhed  a 
level of only "-'1/5 of that in the control cultpres at its peak 
at 42 h. 
These results indical:e that the inhibitory effects of CTLA-4, 
whether mediated by its natural ligand or by antibody cross- 
linking,  can  be  detected  early  in  the  course  of activation 
and are  not due  to precipitous  ter~mnation  of responses at 
later stages in the process. 
CTLA-4 Engagement Does Not Induce Cell Death,  But Pre- 
vents Cell Cycle Progression.  One  mechanism  that  could  ac- 
count for the inhibition of proliferation by CTLA-4 would 
be  the  induction  or enhancement  of cell  death.  Since  the 
inhibition  was  detectable  throughout  the  culture  period, 
we  assessed  the  kinetics  of cell  death  occurring in  T  cell 
cultures.  We  initially  used  hematocytometric  counting of 
cells stained with the vital dye trypan blue to follow the re- 
covery of viable and nonviable cells.  The results are shown 
in  Fig.  2.  It  is  significant  that  the  total  recovery,  of cells 
from  the  cultures  was  essentially  100%  of input,  even  in 
those in which proliferation did not occur. In unstimulated 
cultures,  the  number of nonviable  cells  increases  over the 
culture period, reaching 50% after 54 h. There was a slight 
increase  in  the  number  of dead  cells  recovered  from cul- 
tures stimulated with anti-CD3 alone, especially at the ear- 
lier time points. Consistent with the proliferation data, cul- 
tures  costimulated  with  anti-CD28  yielded  an  increase  in 
viable cells after 42 h, with a total yield of over 300% at 78 h. 
Stimulation  with  anti-CD3  plus anti-CTLA-4 did not re- 
sult  in  an  increase  in dead cells over that observed in .un- 
stimulated cultures or in cultures stimulated with anti-CD3 
alone. There was also no increase in recovery, of dead cells 
from cultures stimulated with anti-CTLA-4 in the presence 
of anti-CD3  and  anti-CD28  over  that  of cultures  stimu- 
lated by anti-CD3  and anti-CD28.  It is perhaps significant 
that  throughout  the  culture  period  the  recovery, of viable 
cells was in fact higher than that from unstimulated cultures 
or cultures stimulated with and-CD3 alone. These data in- 
dicate  that  cross-linking  of CTLA-4 does  not  induce  cell 
death,  at least  as detectable  at  the  level  of membrane  per- 
meability. 
As a more direct and sensitive measure of cell death and 
cell cycle status,  we used propidium iodide staining of per- 
meabihzed cells  to measure DNA content at various stages 
in the cultures. Each culture was started with identical num- 
bers  of cells,  and  equal  fractions of the  cultures were ana- 
lyzed in order to allow a comparison of the absolute num- 
ber of recovered cells in the G0/G1, S/G2, and sub-diploid 
populations.  The results  are presented  in  Fig.  3.  Total  cell 
recovery, was essentially  100% of input or higher under all 
stimulation conditions. Greater than 99~  of input cells were 
in  G0/G1.  In  unstimulated  cultures,  the  number  of cells 
with  sub-diploid  amounts  of DNA indicative  of apoptosis 
increased to slightly greater than  50% of the total over the 
course of the culture period. A similar pattern was observed 
in cultures stimulated with anti-CD3 alone, although slightly 
higher numbers of cells in S/G2 were obtained.  In cultures 
costimulated  with  anti-CD28,  there  was  a  significant  in- 
crease in the number of cells in S/G2 as early as 20 h, and 
this  number increased  progressively over the  assay  period. 
The  DNA  profiles  of cells  stimulated  with  anti-CD3  to- 
gether with anti-CTLA-4 were essentially the some as un- 
stimulated or anti-CD3 stimulated cultures throughout the 
assay  period with  no significant differences in the  number 
of apoptotic cells.  However, there were significantly fewer 
cells  in  S/G2  in  cultures  stimulated  with  anti-CD3  plus 
anti-CTLA-4 relative to stimulation  with anti-CD3  alone. 
Cultures stimulated with anti-CTLA-4 and anti-CD3  plus 
anti-CD28  had similar  numbers or even fewer cells in the 
sub-diploid  population  than  any  of the  other  conditions 
throughout the  culture  period.  Thus there  is n,o evidence 
of induction ofapoptotic cell death by anti-CT_LA-4 cross- 
linking  at  any  time  during  the  course  of activ.ation.  The 
main effeft of cross-linking CTLA-4 on cells sdmuJgted with 
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Figure  2.  CTLA-4  engage- 
ment does not affect T  cell via- 
bility. Purified T  cells (1  X  10 ~ in 
200  itd) were activ,ated  in round- 
bottom wells with 1 X  l0 s of the 
indicated antibodies immobilized 
on latex  microspheres. After the 
indicated  times,  cells  were  re- 
iru~ved,  ~rypan  blue  war  added, 
and  the  yiable  (t~pan  blue  ex- 
cluding)  and  dead  Orypan  blue 
absorbing)  cells  were  counted 
using  a  hero,ocytometer.  10 -4 
ml of each culture was counted from duplicate wells and the value for this volume was multiplied by 2 to obtain a value for the perce~ ofinpm (50 x 
1()4 cells/m/was input). Sta:adard  deviations of duplicate wells were always less than 10% of the mean and this experiment is represermative ef f0ur exper- 
iments. 
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Figure 3.  CTLA-4 cross-linking  prevents cell cycle entry without inducing apoptosis. Purified T cells (1  X 10  s per well in 200 ILl) were activated in 
round-bottom wells with 1 ￿  105 of the indicated antibodies immobilized on latex microspheres. Cultures  were harvested  20, 44, and 68 h after the start 
of the culture and fixed with 80% ethanol. Samples  were all brought up in equal volumes ofpropidium iodide solution and cells were analyzed  for exacdy 
two rain at a fixed flow rate. All events above a forward scatter threshold excepting those with forward/side scatter characteristic ofmicrospheres were 
gated for analysis  of Pl fluorescence and markers were set for sub diploid (M1), G0/G1 (M2), and S/G2 (M3) quantities  to obtain the values  for the num- 
ber of events in each population. This experiment is representative  of six experiments. 
anti-CD3 and anti-CD28 is an inhibition of the increase in 
total viable cells, especially those in S/G2.  Together, these 
results indicate that CTLA-4 engagement inhibits cell cycle 
progression, and an arrest of cells in G0/G1. 
CTLA-4 Engagement Partially Inhibits Induaion of lL-2 Re- 
ceptor Alpha Chain Expression.  Another hallmark of T  cell 
activation is upregulation of expression of CD25,  the IL-2 
receptor alpha chain. We used flow cytometry to assess  the 
expression of CD25  on T  cells under conditions of CD28 
costimulation with and without concomitant CTLA-4  li- 
gation. As shown in Fig. 4, stimulation ofT  cells with anti- 
CD3 alone resulted in the induction of expression of CD25 
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on ~60% of T  cells within 24 h.  Costimulation with anti- 
CD28  increased  this  expression  with  respect  to  both  the 
number of positive cells and the level of expression at 24 h, 
and the expression was further enhanced at 60 h of culture. 
When  CTLA-4  was  also  engaged,  CD25  expression  was 
expressed by a  smaller fraction  of the  cells  (47% vs.  80%) 
and the mean level of expression was much lower at 24  h 
(MFI  162 vs.  194) and at 60 h  (MFI 332 vs. 669) relative to 
cultures  costimulated with  anti-CD28.  This  data  demon- 
strate  that  CTLA-4  engagement inhibits the  upregulation 
of CD25  throughout  activation.  The  mechanism  for  the 
inhibition is not certain. Since IL-2 has been shown to up- Time  c~l 
24h  "~ 
Z~ 
60h 
aCD31Ctrl 
!t  .p 
aCD3/aCD28/Ctrl aCD3/aCTLA-4/Ctrl  aCD3/aCD28/ 
aCTLA-4 
IrllilO'~l~  le" 
CD25 Expression 
Figure 4.  Expression  of CD25 
on activated T  cell populations. 
Purified CD4+ T cells  were acti- 
vated using microsphere-immo- 
bilized antibodies as described in 
the  legend to  Fig. 3.  After the 
indicated  time,  cells were  re- 
moved, washed once with PBS/ 
1% calf serum and stained with 
either anti-CD25.FITC  or con- 
trol Rat lgG.FITC. Cell popula- 
tions were analyzed by flow cy- 
tometry.  Markers were  set  for 
the negatives and the mean fluo- 
rescence  of  cells above  that 
threshold (X =  ), and percentage 
of  cells staining above  that 
threshold  was  calculated using 
the Lysis  II program. 
regulate CD25  in human  peripheral T  cells and in murine 
T  cell clones (25,  26),  inhibition of its expression may be 
an indirect consequence  of the inhibition of IL-2 produc- 
tion by CTLA-4.  On the other hand,  it has been recently 
reported that CD28 costimulation can directly induce CD25 
expression on virgin murine  T  cells by an  IL-2 indepen- 
dent mechanism  (27).  Our previous observation that  IL-2 
did not  fully restore proliferation to  cultures inhibited by 
CTLA-4  (7)  implies that  CTLA-4  may  directly interfere 
with this process. Whatever the mechanism, our results dem- 
onstrate that  CTLA-4  engagement  can  interfere with  an- 
other early feature ofT  cell activation, CD25 upregulation. 
CTLA-4 Engagement Partially Inhibits Expression of the Early 
Activation Marker CD69.  CD69  is  an  early  and  transient 
marker of T  cell activation (28).  In Fig. 5 we present a ki- 
netic analysis of the effects of CD28  and CTLA-4 engage- 
ment  on  induction  of CD69  expression.  At  12  h,  CD69 
was expressed by greater than 50% ofT  cells activated with 
CD3  alone  or costimulated with  anti-CD28,  while fewer 
than  15%  of costimulated cells also subjected to  CTLA-4 
ligation were positive. At 24  h,  CD69  expression was  de- 
tectable, albeit in a heterogeneous pattern, on greater than 
75%  of CD28  costimulated cells. At this point fewer than 
45%  of cells from cultures in which CTLA-4 had also been 
engaged expressed  CD69  and  the  level  of expression was 
reduced. By 36 h, CD69 expression had returned to essen- 
tially resting levels in all the cultures. Thus,  it appears that 
CD28  costimulation augments  and  prolongs CD69  expres- 
sion, whereas CTLA-4 ligation inhibits the initial upregula- 
tion of CD69.  This result is consistent with the observation 
that CD69 levels were found to be constitutively elevated on 
T  cells isolated from  CTLA-4-deficient mice  (10,  11)  and 
provides additional evidence suggesting a role for CTLA-4 in 
preventing the early induction of T  cell activation. 
Discussion 
While it has become apparent CTLA-4 has an important 
role in downregulating T  cell responses, the mechanism by 
which  this is  accomplished is not  at  all clear.  It has been 
suggested that CTLA-4 terminates responses of activated T 
cells, perhaps by induction of apoptotic cell death (14,  15). 
Here we have demonstrated that CTLA-4 mediates inhibi- 
tion of proliferation and IL-2 production by resting T  cells 
in the absence of CTLA-4-mediated cell death. We found 
that  the  recovery of viable and  nonviable cells from  anti- 
Time  CD3 
m: 
~Zh 
I-,w 
Z 
36 h 
L 
~.,e. 
CD3/CD28 
m, 
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CD3/CDZ8/ 
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Figure 5.  Expression of CD69 on activated T cell populations. Purified 
CD4+ T cells were activated using microsphere-immobilized antibodies 
as described in the legend to Fig. 3. After the indicated time, cells were 
removed, washed once with PBS/I%  calf serum, and then stained with 
either control RatlgG FITC or with anti-CD69 FITC. 5,000 live gated 
events were collected for each sample. This experiment is representative 
of three individual trials. 
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control antibody or anti-CD3 stimulated cultures. We found 
no evidence for the accumulation  of cells with sub-diploid 
quantities of DNA associated with apoptotic cell death even 
1-2  d  after inhibitory  effects of CTLA-4  cross-linking are 
first observed at the level of proliferation and IL-2 production. 
Finally,  CTLA-4  cross-linking  arrests  T  cells  in  a  G0/G1 
phase  of the  cell  cycle.  Taken  together,  these  data  clearly 
demonstrate that inhibition  of T  cell prohferation and IL-2 
secretion  by  CTLA-4  can  occur  in  the  absence  of cell 
death. 
At least two possible explanations  may be offered to ac- 
count for the discrepancy between our results and an earlier 
report of apoptotic cell death resulting from CTLA-4 liga- 
tion  (15).  This study examined the  effect of CTLA-4 liga- 
tion upon restimulation of a long-term human T  cell clone 
whereas we have examined the effect of CTLA-4 on freshly 
isolated murine T  cells. Another possibility is that CTLA-4 
might have indirectly contributed to the death of the T  cell 
clone  by  depriving  it  of an  essential  growth  and  survival 
factor by the  cessation of IL-2 production.  This possibility 
is supported by the  observation that the apoptotic death in 
these  clones  was prevented  by the  addition  of exogenous 
IL-2 (15). 
An  important  implication  of the  data  presented  here  is 
that CTLA-4 may have a role in regulating T  cell responses 
at  early stages  in  the  process.  CTLA-4  has  not  been  de- 
monstrable  by  flow  cytometry  on  resting  T  cells,  and 
reaches  maximal  levels  only  1-2  d  after  activation  (5-7). 
This has led to the notion that CTLA-4 is an activation an- 
tigen whose main role is to terminate ongoing responses (3, 
12).  Our  data  do  not  reveal  a  precipitous  termination  of 
ongoing  responses,  but  rather  an  inhibition  and  delay  of 
events associated with the progression of T  cell activation. 
We observed that inhibition  of the upregulation  of the ac- 
tivation marker CD69 was detectable by 12 h, inhibition  of 
IL-2 production was observed by 16 h, and the initiation of 
proliferation  at  24  h  was  delayed.  Despite  the  fact  that 
CTLA-4 expression has been undetectable by the relatively 
insensitive  method  of flow cytometry until later after acti- 
vation, our assays reveal the presence of functionally signif- 
icant levels much earlier than has been appreciated. 
These observations lead us to speculate that CTLA-4 may 
have  an  important  role  in  regulating  both  initiation  and 
termination  of T  cell responses.  Even though  it is initially 
expressed at very low levels, the higher affinity of CTLA-4 
for the  common B7 ligands  may give it a  competitive ad- 
vantage over CD28 for binding when these ligands are bru- 
iting.  Thus,  when  a  T  cell encounters  an antigen  on pre- 
senting cell which  express only modest amounts of B7,  for 
example a resting B cell (29), CTLA-4 may dominate and pre- 
vent the initiation of the response. This notion is consistent 
with our observation that the level of B7-2 expressed by T 
cells themselves is insufficient  to provide costimulation for 
anti-CD3  stimulated  cells,  but  can at least partially inhibit 
CD28-mediated  costimulation ((reference 7) and Fig.  1 A). 
However, in an encounter  with an antigen presenting  cell 
with  high  levels  of B7  expression,  such  as  an  activated B 
cell,  macrophage,  or  dendritic  cell  (29,  30),  the  level  of 
CTLA-4 would be hmiting allowing the costimulatory ac- 
tivity of CD28  to dominate and the activation to proceed. 
With time and the upregulation of CTLA-4, the inhibitory 
effect would again become dominant and the responses ter- 
minate.  CTLA-4 mediated termination  of T  cell responses 
may allow some cells to evade activation induced cell death 
(31)  and become memory cells,  ready to again respond  to 
antigen upon the decay of CTLA-4 expression. 
The  precise role  of CTLA-4  in  regulating  T  cell func- 
tions in the  early and late stages of responses remain to be 
established.  However,  our  data  clearly  demonstrate  that 
CTLA-4 engagement can counteract  the  costimulatory ef- 
fect of anti-CD28  on multiple  aspects of the  activation of 
resting T  cells. CTLA-4 mediated inhibition  of T  cell pro- 
liferation is a  consequence  of cell cycle arrest, perhaps as a 
consequence  of inhibition  of IL-2 production,  and  is  not 
due to induction  of cell death. 
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